ALLMedicine™ Intestinal Obstruction Center

Mar 23rd, 2023 - Identification of reliable risk-stratification tools is critical for surgical decision making, particularly in frail and elderly. The aim of the study is to validate the Emergency Surgery Frailty Index (EmSFI), in over 65 years old patients operat...

Mar 16th, 2023 - Practice Essentials Each year in the United States, many patients undergo resection of long segments of small intestine for various disorders, including inflammatory bowel disease (IBD), malignancy, mesenteric ischemia, and others. Juvenile surviv...

Mar 16th, 2023 - Practice Essentials Each year in the United States, many patients undergo resection of long segments of small intestine for various disorders, including inflammatory bowel disease (IBD), malignancy, mesenteric ischemia, and others. Juvenile surviv...

Mar 16th, 2023 - Practice Essentials Each year in the United States, many patients undergo resection of long segments of small intestine for various disorders, including inflammatory bowel disease (IBD), malignancy, mesenteric ischemia, and others. Juvenile surviv...

Mar 13th, 2023 - Approach Considerations The treatment of hypokalemia has four facets, as follows: Reduction of potassium losses Replenishment of potassium stores Evaluation for potential toxicities Determination of the cause to prevent future episodes, if possibl...

Feb 11th, 2016 - This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the removal of foreign bodies in the upper gastrointestinal tract in adults. Recommendations Nonendoscopic measures 1 ESGE recommend...

Mar 6th, 2023 - The goal of this study is planing to adopt intra-abdominal perfusion therapy of rmhTNF during radical colorectal cancer surgery to determine whether intra-abdominal therapy has an impact on postoperative intestinal function recovery, anastomotic l...

Mar 1st, 2023 - Gastrointestinal symptoms that cause discomfort in patients and reduce their quality of life and comfort include disorders related to the esophagus, stomach, duodenum, jejunum, ileum, large intestine, sigmoid colon and rectum. These symptoms: refl...

Feb 24th, 2023 - Postoperative intra-abdominal adhesions are a common cause of small bowel obstruction. The extent of adhesions has been assigned to the magnitude of previous surgery. In a county hospital, with a catchment population of 120 000 inhabitants, record...

Feb 14th, 2023 - More than 70% of patients with cancer in the palliative phase have pain that often requires treatment with opioids (morphine-like agents). Constipation occurs in 59% of patients treated with opioids. Opioid-induced constipation (OIC) has consequen...

Feb 6th, 2023 - Incisional hernia (IH) is a common complication of abdominal wall surgery. Its' incidence varies greatly (2-30 %) among studies. The incisional hernia incidence is influenced by several factors, such as closing technique, follow-up time and the mo...

Jan 19th, 2023 - The FDA has granted accelerated approval to tucatinib (Tukysa) in combination with trastuzumab (Herceptin) for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer who have progressed following treatment wi...

Jan 12th, 2023 - Neoadjuvant immunotherapy with PD-1 inhibitors led to objective responses in 85% of patients with localized and locally advanced colorectal cancer (CRC) with mismatch repair deficiency (dMMR)/high microsatellite instability (MSI-H), a retrospectiv...

Nov 17th, 2022 - The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment of adult patients with folate receptor α (Frα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, wh...

Nov 15th, 2022 - The FDA has approved the VENTANA FOLR1 (FOLR1-2.1) RxDx assay, the first immunohistochemistry (IHC) companion diagnostic test to help identify patients with epithelial ovarian cancer who are eligible for treatment with mirvetuximab soravtansine-gy...

Nov 2nd, 2022 - The administration of trilaciclib (Cosela) prior to treatment with sacituzumab govitecan-hziy (Trodelvy) meaningfully reduced adverse effects (AEs) related to the antibody-drug conjugate (ADC) in patients with unresectable locally advanced or meta...